Get started
Author

Dilek Çağlayan

Observed names: D Caglayan, D. Cağlayan, Dilek Caglayan, Dilek ÇAĞLAYAN, Dilek Çağlaya, Çağlayan, Dilek
ORCID: 0000-0003-4629-6815
Observed ORCID: 0000-0003-4629-6815
OpenAlex ID: A5057280650
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer
2022 · Dilek Çağlayan, Mehmet Zahid Koçak, et al. · European Journal of Clinical Pharmacology · 23
PDF
The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients
2024 · Dilek Çağlayan, Mehmet Zahid Koçak, et al. · Future Oncology · 9
PDF
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
2024 · Elif Şenocak Taşçı, Başak Oyan, et al. · BMC Cancer · 9
PDF
Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab
2025 · Esra Zeynelgil, Dilek Çağlayan, et al. · Journal of Inflammation Research · 8
PDF
The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.
2022 · Dilek Çağlayan, Mehmet Zahid Kocak, et al. · Journal of Clinical Oncology · 8
Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
2013 · A Kuzhan, M Adli, et al. · PubMed · 8
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
2022 · Emre Yekedüz, Mehmet Fatih Özbay, et al. · European Journal of Clinical Pharmacology · 5
PDF
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study
2023 · Muzaffer Uğraklı, Mehmet Zahid Koçak, et al. · Journal of Cancer Research and Clinical Oncology · 4
PDF
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma
2022 · Selin Aktürk Esen, Yakup Ergun, et al. · Bosnian Journal of Basic Medical Sciences · 4
Extensive metastatic ependymoma with long-term progression-free survival with capecitabine plus temozolomide combination chemotherapy: A case report
2023 · Engin Hendem, Mustafa Korkmaz, et al. · Journal of Cancer Research and Therapeutics · 3
235P The impact of body mass index (BMI) on the progression-free survival of CDK4/6 inhibitors in metastatic breast cancer patients (MBC)
2022 · M. Artac, D. Cağlayan, et al. · Annals of Oncology · 3
Is pancreatic giant cell tumor resistant to standard chemotherapy?
2022 · Dilek Çağlayan, Melek Karakurt Eryilmaz, et al. · Anti-Cancer Drugs · 3
Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
2024 · Elif Şenocak Taşçı, Başak Oyan, et al. · BMC Cancer · 2
PDF
Evaluating the effect of tumor size and sidedness on prognosis in stage 2 colon cancer: a retrospective population study.
2022 · H Demir, D Caglayan, et al. · PubMed · 2
The Impact of the COVID-19 Pandemic on Follow-Up and Management of Cancer Patients
2021 · Melek KARAKURT ERYILMAZ, Mustafa KARAAĞAÇ, et al. · Journal of Oncological Sciences · 2
PDF
Safe use of ribociclib in a patient with HR+/HER2− metastatic breast cancer receiving chronic hemodialysis
2026 · Dilek Çağlayan, Melek Çağlayan · Journal of Oncology Pharmacy Practice · 1
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study
2026 · Engin Hendem, Mehmet Zahid Koçak, et al. · Medicina · 1
PDF
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
2025 · Neslihan Özyurt, Ali Alkan, et al. · Scientific Reports · 1
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
2024 · Neslihan Özyurt, Ali Alkan, et al. · Scientific Reports · 1
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study
2024 · Özgecan Dülgar, Sema Türker, et al. · Journal of Chemotherapy · 1
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
2024 · Elif Şenocak Taşçı, Yasin Kutlu, et al. · Expert Opinion on Pharmacotherapy · 1
FGFR 1–3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis
2026 · Dilek Çağlayan, Emine Göktaş, et al. · Medicina
Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study
2026 · Muzaffer Uğraklı, Ülkü Kerimoğlu, et al. · Medicina
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
2026 · Neslihan Özyurt, Ali Alkan, et al. · Cancers
PDF
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study
2025 · Bilgeşah Kılıçtaş, Murat Araz, et al. · Journal of Chemotherapy
Works count: 32
Citation count: 99
H-index: 6
I10-index: 1
Year
Topic
Type